Journal article
Phase II single arm open label multicentre clinical trial to evaluate the efficacy and side effects of a combination of gefitinib and methotrexate to treat tubal ectopic pregnancies (GEM II): Study protocol
AW Horne, MM Skubisz, A Doust, WC Duncan, E Wallace, HOD Critchley, TG Johns, JE Norman, S Bhattacharya, J Mollison, M Rassmusen, S Tong
BMJ Open | BMJ PUBLISHING GROUP | Published : 2013
Abstract
Introduction: Tubal ectopic pregnancy (tEP) is the most common life-threatening condition in gynaecology. tEPs with pretreatment serum human chorionic gonadotrophin (hCG) levels 1000 IU/L take a significant time to resolve with MTX and require multiple outpatient monitoring visits. Gefitinib is an orally active epidermal growth factor receptor (EGFR) antagonist. In preclinical studies, we found that EP implantation sites express high levels of EGFR and that gefitinib augments MTX-induced regression of pregnancy-like tissue. We performed a phase I toxicity study administering oral gefitinib and intramuscular MTX to 12 women with tEPs. The combination therapy did not cause significant toxiciti..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
This work is supported by an NHMRC Grant (# 1008276) to ST, TJ and EW, and an MRC Centenary Award (G0802808) to AH. The funders will have no role in the study design; collection, management, analysis and interpretation of data; writing of the report; and the decision to submit the report for publication.